



Dental surgery in anticoagulated patients—stop the interruption

Michael J. Wahl, DDS,^a Andres Pinto, DMD, MPH,^b Jessica Kilham, MLIS,^c and Rajesh V. Lalla, DDS, PhD, CCRP^d

In a literature review, the incidence and morbidity of bleeding complications after dental surgery in anticoagulated patients was compared with embolic complications when anticoagulation was interrupted. Over 99% of anticoagulated patients had no postoperative bleeding that required more than local hemostatic measures. Of more than 5431 patients undergoing more than 11,381 surgical procedures, with many patients at higher than present therapeutic intentional normalized ratio (INR) levels, only 31 (~0.6% of patients) required more than local hemostasis to control the hemorrhage; none died due to hemorrhage. Among at least 2673 patients whose warfarin dose was reduced or withdrawn for at least 2775 visits for dental procedures, there were 22 embolic complications (0.8% of cessations), including 6 fatal events (0.2% of cessations). The embolic morbidity risk in patients whose anticoagulation is interrupted for dental surgery exceeds that of significant bleeding complications in patients whose anticoagulation is continued, even when surgery is extensive. Warfarin anticoagulation, therefore, should not be interrupted for most dental surgery. (*Oral Surg Oral Med Oral Pathol Oral Radiol* 2015;119:136-157)

Vitamin K antagonists such as warfarin are commonly used in patients with atrial fibrillation, artificial heart valves, deep vein thrombosis, myocardial infarction, and pulmonary embolisms. Ever since the first report of excessive bleeding after dental extractions in 1957,¹ dental surgery in anticoagulated patients has been controversial and the subject of avid interest among physicians and dentists, who must weigh the bleeding risks in anticoagulated patients versus the risks of embolic complications in patients whose anticoagulation is reduced or withdrawn.

Dental surgery, including simple and surgical tooth extractions, is unlike surgery performed on most other parts of the body. Major blood vessels are unlikely to be encountered, and the surgical sites are easily accessible to local hemostatic methods, including pressure application (biting on gauze), cellulose, gelatin foams, hemcon dressing, microfibrillar collagen, sutures, hemostatic solutions (styptics), tannic acid, tranexamic acid, and fibrin glue.²

Sequential literature reviews in 1998³ and 2000⁴ demonstrated that bleeding complications requiring more than local hemostatic measures after dental surgery at therapeutic anticoagulation levels are exceedingly rare. On the other hand, sometimes fatal embolic

complications can occur when anticoagulation is withdrawn or reduced for dental procedures. Of over 2400 dental surgical procedures in over 950 patients, only 12 patients (<1.3%) suffered bleeding complications requiring more than local hemostatic measures. Of 575 cessations of warfarin for dental procedures, there were 5 embolic complications (0.95%) and 1 fatal outcome. The conclusion was that continuous anticoagulation at therapeutic INR levels should not be interrupted for dental surgery with local hemostatic measures. The purpose of the present review is to update the previous findings with the inclusion of additional literature.

Since 2000, most authors have concurred that continuous therapeutic levels of anticoagulation (up to INR 3.5, or sometimes 4.0) should not be withdrawn or reduced or replaced with heparin for dental surgery.⁵⁻¹² Beirne concluded, "The risk of uncontrolled life-threatening bleeding is so low that it is not necessary to stop anticoagulation [INR 2.0 to 4.0] even for a short interval and risk thromboembolism in patients on oral anticoagulants."¹³ Although not the subject of this article, the use of newer anticoagulants, including direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban), has not been studied as extensively as that of warfarin, but it does not appear

^aChristiana Care Health System, Wilmington, Delaware, USA.

^bUniversity Hospitals Case Medical Center and Department of Oral and Maxillofacial Medicine and Diagnostic Sciences, Case Western Reserve University, Cleveland, Ohio, USA.

^cPublic Services Librarian, Edward and Barbara Netter Library, Quinnipiac University, Hamden, Connecticut, USA.

^dSection of Oral Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.

Received for publication Aug 1, 2014; returned for revision Sep 6, 2014; accepted for publication Oct 15, 2014.

© 2015 Elsevier Inc. All rights reserved.

2212-4403/\$ - see front matter

<http://dx.doi.org/10.1016/j.oooo.2014.10.011>

Statement of Clinical Relevance

The risk of postoperative bleeding complications in patients in whom anticoagulation is continued for dental surgery is exceedingly small and is outweighed by the small risk of serious and sometimes fatal embolic events when anticoagulation is interrupted for dental surgery.

necessary to withdraw such medications for dental surgery.¹⁴

The inclusion criteria for article selection were English language peer-reviewed publications that reported on bleeding complications or thromboembolic events in human patients in whom warfarin therapy was continued unchanged, altered, or interrupted for a dental procedure. Literature searches were performed in NLM PubMed and Scopus for citations included in the databases up to October 10, 2013. Other retrieval methods included cited reference searching and manual searching of the literature. Search terms used included “oral surgical procedures,” “oral surgery,” “tooth extraction,” “dental scaling,” “dental procedures,” “warfarin,” “anticoagulant,” “surgical blood loss,” “oral hemorrhage,” “postoperative hemorrhage,” “hemostasis altering,” “thromboembolism,” “stroke,” “adverse event,” “risk assessment,” and “treatment outcome.”

DENTAL SURGERY IN PATIENTS WITH CONTINUOUS WARFARIN ANTICOAGULATION

We reviewed 83 clinical studies of dental surgery in more than 5431 patients who were continuously anticoagulated with vitamin K antagonists and underwent more than 11,381 dental surgical procedures, including more than 10,322 dental extractions (Table I).^{1,15-96} Many of these studies showed similar incidences of postoperative bleeding or blood loss after dental surgery between continuously anticoagulated patients, patients whose anticoagulation was reduced or withdrawn, and nonanticoagulated patients.^{17,18,22,23,37,53,65,95} Out of more than 5431 patients at greater than 5677 visits undergoing more than 11,381 surgical procedures, there were only 375 cases (~6.6% of patient visits) of minor postoperative bleeding that required additional local measures for hemostasis. Only 31 cases (~0.6% of patient visits) required more than local hemostatic measures to control hemorrhage. Thus, more than 99% of all patients had no postoperative bleeding that required more than local hemostatic measures. These studies confirm the earlier findings that for continuously anticoagulated dental patients, there is an exceedingly small risk of a significant postoperative bleeding complication (requiring more than local hemostatic measures).

Analysis of some cases of postoperative hemorrhage requiring more than local hemostatic measures

Cieślak-Bielecka et al.⁴⁵ studied 40 continuously anticoagulated patients undergoing 186 dental surgical

procedures, including 181 extractions with local hemostatic measures. Two patients (undergoing 3 extractions at INR 3.5 and 6 extractions at INR 3.0) who had “minor bleeding” 2 and 3 days postoperatively were treated with new sutures and intravenous cyclonamine. Some patients were on additional medications, including aspirin, but it is unclear which patients or what local measures other than new sutures were attempted before administering cyclonamine.

Morimoto et al. studied three groups of 382 patients undergoing simple and surgical dental extractions on continuous antithrombotic therapy.^{71,72} The first group was on warfarin monotherapy, the second group was on warfarin and antiplatelet combination therapy, and the third was on antiplatelet monotherapy. Hemostasis was achieved in all patients with local measures, but one patient on combined warfarin–antiplatelet therapy undergoing three extractions at INR 1.5 was also administered vitamin K because of an “excessively high” postoperative INR level that was impossible to measure.

Hong et al. studied 122 anticoagulated dental surgical patients,⁶³ some of whom were on additional medications thought to enhance anticoagulation. Only one patient (following liver transplantation, with end-stage renal disease and on hemodialysis) on combined warfarin–aspirin therapy required more than local hemostatic measures after 5 extractions at INR 2.2. His anticoagulation was INR 5.9 after hospital admission. Vitamin K and fresh frozen plasma were administered and local hemostatic measures applied.

All of the above four patients requiring more than local hemostatic measures underwent 3 or more extractions. The authors reported that at least 2 (and possibly all 4) patients had very high postoperative INR levels, possibly because of concomitant medications and/or medical history. These very high INR levels may have contributed to the bleeding complications, and in each study, the authors concluded that therapeutic levels of anticoagulation should not be interrupted for dental surgery.

ANTICOAGULATION WITHDRAWAL OR REDUCTION FOR DENTAL PROCEDURES

We reviewed 64 studies of more than 2673 patients whose anticoagulation was withdrawn or reduced for more than 2775 appointments for dental surgery.^{1,17,18,20,25,31,35-37,40,48,49,51,53,57,58,61,65,71,74,79,82,83,86,87,91,94,96-132}

There were 161 patients (~6% of patients and visits) with at least minor postoperative bleeding, including 4 patients (0.14% of visits) who were administered more than local measures for hemostasis. There were 22 embolic complications (0.8%), including 6 that were fatal (Table II).

Table I. Dental surgery in continuously anticoagulated patients

<i>Source</i>	<i>No. of patients (pts) treated (visits)</i>	<i>No. of surgical procedures</i>	<i>No. of extractions</i>	<i>International normalized ratio (INR)</i>	<i>Comment</i>	<i>Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)</i>	<i>Bleeding complications requiring more than local measures</i>
Al Zoman et al. 2013 ¹⁵	2 (2)	2	0	4.1 and 4.0 on the days of the procedures		0	0
Al-Belasy & Amer 2003 ¹⁶	30 (30)	155	155	1.7-4.3		5	0
Al-Mubarak et al. 2006, ¹⁷ 2007 ¹⁸	110 (110)	>110	>110	Mean 2.4-2.7		8	0
Alexander et al. 2002 ¹⁹	15 (15)	28	27	1.9-3.6 (mean 2.57)	All 27 extractions were surgical	0	0
Anavi et al. 1981 ²⁰	15 (15)	52	52	PT 19%-36%; mean 27.5% [INR <2.5 to INR >3.0]		7	0
Askey & Cherry 1956 ²¹	6 (10)	14	14	Prothrombin concentration 14%-51% [INR <2.0 to INR >3.5]		0	0
Bacci et al. 2010 ²²	451 (451)	926	926	1.8-4.0 (mean 2.14)	379 extractions were surgical	7	0
Bacci et al. 2011 ²³	50 (50)	159	0	1.8-4.0	All were single or multiple implant placement	2	0
Bailey & Fordyce 1983 ²⁴	25 (25)	156	156	PT ratio 1.2 to 4.3; mean PT ratio 2.4		59	0
Bajkin et al. 2009 ²⁵	109 (109)	194	194	1.68-4.0 (mean 2.45)		4	0
Bajkin et al. 2012 ²⁶	213 (213)	142	235	Mean 2.43-2.45	71 were on combined warfarin–aspirin	5 (INR 2.32-3.45)	0
Bakathir 2009 ²⁷	124 (124)	157	149	2.1-3.5 (mean 2.8)	26 extractions were surgical	6	0
Bal & Hardee 2000 ²⁸	50 (50)	104	104	2-4.5	Tranexamic acid	0	0

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Bandrowsky et al. 1996 ²⁹	1 (1)	21	20	INR 3.51 preop; INR 9.03; 96 hr postop	tranexamic acid	0	1 pt with good hemostasis 72 hr after surgery. Amoxicillin 500 mg three times daily for 7 days after surgery was prescribed as prophylaxis. On 4th postoperative day, pt was bleeding and INR 9.03. Coumadin withheld, and pt transfused with fresh-frozen plasma, then packed red blood cells, and ultimately vitamin K. Authors conclude the elevated PT was from interaction with amoxicillin and that the amoxicillin was probably unnecessary.
Barrero et al. 2002 ³⁰	125 (229)	367	367	2.0-3.0	Postoperative tranexamic acid mouthwash	1	1 required transfusion
Behrman & Wright 1961 ³¹	16 (16)	41	31	PT ratio 1.2-2.5		0	0
Benoliel et al. 1986 ³²	> 3 < 30 (≥3)	87	87	PT ratio 1.3-2.5		1	0
Blinder et al. 1999 ³³	150 (150)	359	359	1.5-4.0 (mean 2.19-2.7)	Some had tranexamic acid mouthwash	13	0
Blinder et al. 2001 ³⁴	249 (249)	543	543	1.5->3.5 (mean ~2.49)		30	0
Borea et al. 1993 ³⁵	15 (15)	15	15	INR between 3.0 and 4.5; mean INR 3.09	Tranexamic acid	1	0
Brooks 2011 ³⁶	1 (1)	1	1	2.5 (5.0 at hospital admission)	Pre- and postoperative amoxicillin also prescribed	1	1 fresh frozen plasma transfusion on 11th postoperative day

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Campbell et al. 2000 ³⁷	12 (12)	40	38	1.2-2.9 (mean 2.0)		0	0
Candemir et al. 2010 ³⁸	1 (1)	1	1	4.4; 10 days after procedure		0	0
Cañigral et al. 2010 ³⁹	19 (19)	19	19	Not reported		1	0
Cannon & Dharmar 2003 ⁴⁰	25 (25)	72	70	2.1-4.0 (average 3.4)		3	0
Carter & Goss 2003 ⁴¹	85 (85)	152	152	2.0-4.0 (average 2.75)		3	0
Carter et al. 2003 ⁴²	1 (1)	1	1	3.8	Fibrin glue used for surgery extraction	0	0
Carter et al. 2003 ⁴³	49 (49)	152	152	2.1-4.0 (mean 3.0-3.1)		2 (1 pt INR 3.6 day of surgery and 5.9, 7th postoperative day; 1 pt INR 2.2 day of surgery and 7.9, 3rd postoperative day)	0
Cesar & Itturiaga 2007 ⁴⁴	1 (1)	1	1	2.6	Tranexamic mouthwashes	1	1 transfused with packed red blood cells and administered vitamin K and full anticoagulation with enoxaparin started, and bleeding continued. Finally controlled with desmopressin. The authors theorize that the LMWH caused the bleeding.
Cieślak-Bielecka et al. 2005 ⁴⁵	40 (≥42)	186	181	1.0-4.0		2	2 described as "minor bleeding complications" treated with additional sutures and cyclonamine. 1 pt had 3 teeth removed at INR 3.5; 1 pt had 6 teeth removed at INR 3.0
Cone 1993 ⁴⁶	1 (1)	1	1	INR 1.5		0	0

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Dantas et al. 2009 ⁴⁷	26 (26)	47	46	1.8-3.8		1	0
Davies 2003 ⁴⁸	~24 (~24)	~≥24	~≥24	Not reported		0	0
Devani et al. 1998 ⁴⁹	33 (33)	69	69	INR 2.2-3.9 (mean 2.7)		1	0
Eichhorn et al. 2012 ⁵⁰	637 (637)	934	88	1.2-4.2 (mean 2.44)		47	2 (anticoagulant changed for 6 days)
Elad & Findler 2008 ⁵¹	≥ 2 ≤ 498 (≥2)	≥2	≥2	Not reported	Periodontal surgery	2 INR ≥3.5	0
Elad et al. 2010 ⁵²	2 (2)	2	2	1.88-2.0		0	0
Evans et al. 2002 ⁵³	57 (57)	114	114	1.2-4.7 (mean 2.5)		5	0
Ferrieri et al. 2007 ⁵⁴	255 (334)	≥1197	≥1177	1.3-5.4 (mean 1.4-3.4)	81 were "complicated"	5	0
Frank et al. 1963 ⁵⁵	11 (11)	51	51	PT activity from 35% to 15% [INR <2.5 to INR 3.5]		0	0
Gagneja et al. 2007 ⁵⁶	1 (1)	6	6	2.97	Clindamycin prophylaxis	0	0
Gaspar et al. 1997 ⁵⁷	32 (32)	≥57	≥57	INR 1.9-3.5 (mean 2.5)	Tranexamic acid mouthwash	2	0
Giuffrè et al. 2006 ⁵⁸	156 (156)	~≥156	~≥156	2.0-3.5	Amoxicillin + clavulanic acid prophylaxis; 104 given platelet-rich plasma, 52 given tranexamic acid soaked gauze for hemostasis	40	6 pts in the tranexamic acid group required vitamin K for hemostasis
Goodchild & Donaldson 2013 ⁵⁹	1 (1)	6	6	2.8		1	0
Greenberg et al. 1972 ⁶⁰	13 (13)	27	27	PT activity 28%-14% [INR >2.5 to INR >3.5]		0	0
Hadziabdic et al. 2011 ⁶¹	50 (50)	≥50	≥50	0.96-2.89		2	1 anticoagulant withdrawn for 1 day postoperatively
Halfpenny et al. 2001 ⁶²	46 (46)	79	79	2.0-4.1, mean 2.7-2.9	13 were surgical; 1 pt with intermittent bleeding admitted to hospital	3	0

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Hong et al. 2012 ⁶³	~105 (105)	252	248	1.1-3.3, mean 2.0	≥ 1 surgical	5	1 pt (post–liver transplantation, end-stage renal disease, and hemodialysis) on combined warfarin–aspirin therapy, who had undergone 5 extractions at INR 2.2. At hospital admission, anticoagulation was INR 5.9. Vitamin K and fresh frozen plasma were administered, and local measures for hemostasis were applied.
Inchingolo et al. 2011 ⁶⁴	193 (193)	≥193	~≥193	Not reported	Tranexamic acid	0	0
Karsli et al. 2011 ⁶⁵	13 (13)	13	13	Mean 2.6		0	0
Kovács et al. 1976 ⁶⁶	31 (31)	56	53	Prothrombin level 19 to 49% (average 33.3%) [INR <2.0 to INR >3.0 average INR <2.5]		0	0
Kusafuka et al. 2013 ⁶⁷	18 (18)	35	35	1.08-2.91 (mean 1.75)	1 extraction surgical	0	0
Kwapis 1963 ⁶⁸	60 (60)	>85	>82	PT ratios not given		0	3 pts (2 with single extractions and PT less than 1.5 the control) had “prolonged bleeding” and administered vitamin K. (Not known if local measures to control hemostasis were attempted.)
Martinowitz et al. 1990 ⁶⁹	40 (40)	63	63	INR 2.5-4.29; average INR 3.25		1	0
McIntyre 1966 ⁷⁰	106 (106)	636	636	Thrombotest generally 15% to 7% [INR 2.1 to INR 3.6]		1	1 pt whose thrombotest was 5% [INR 4.8] bled for 12 hr after 9 extractions and administered vitamin K.

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Morimoto et al. 2008, ⁷¹ 2011 ⁷²	254 (292)	533	533	1.5-2.96 in the 15 pts with postoperative hemorrhage	18 pt were on combined warfarin-antiplatelet therapy; 68 extractions were surgical	15	1 pt (INR 1.50) on warfarin—antiplatelet combination therapy administered vitamin K because of “markedly prolonged” INR level that was unable to be measured 5 days after 3 extractions
Morimoto et al. 2009 ⁷³	≥36 (≤52)	52	0	≤2.97	11 pts on combined warfarin—antiplatelet	1	0
Nakasato et al. 1989 ⁷⁴	23 (23)	≥23	≥23	Not reported		0	0
Pereira et al. 2011 ⁷⁵	107 (107)	~214	~214	0.8-4.9, mean 3.15	9 pts on combined warfarin—aspirin	1	0
Raborn et al. 1990 ⁷⁶	17 (17)	17	17	Average (7 pts): PT 15/11.5; (10 pts): 18.4/11.5		0	0
Ramli & Rahman 2005 ⁷⁷	21 (30)	44	44	1.89-3.5	Tranexamic acid mouthwash	1	0
Ramstrom et al. 1993 ⁷⁸	89 (89)	~137	~133	INR 2.1-4.0	Tranexamic acid or placebo mouthwash	9	1 administered vitamin K (5 mg) after local measures. INR not given.
Sacco et al. 2007 ⁷⁹	65 (65)	>100	>100	Mean 2.89		6	0
Salam et al. 2007 ⁸⁰	150 (150)	279	279	0.9-4.2 (mean 2.5)	30 extractions were surgical	10	0
Sammartino et al. 2011 ⁸¹	50 (50)	168	168	Mean 3.16		2	0
Sammartino et al. 2012 ⁸²	53 (≥53)	173	173	2.0-4.0	Tranexamic acid	2	0
Schmitt 1961 ⁸³	1 (1)	6	6	PT 39 seconds (~40%)		0 (hematoma)	0
Shira RB et al. 1962 ⁸⁴	18 (18)	50	45	PT 16.8 seconds to 50.7 seconds [PT ratio 1.4 to 4.225]	Gelfoam and sutures placed for most extractions	6	1: PT 12.5% 35.4 seconds [PT ratio 2.95] (extraction with suture but no Gelfoam) given vitamin K.

(continued on next page)

Table I. Continued

Source	No. of patients (pts) treated (visits)	No. of surgical procedures	No. of extractions	International normalized ratio (INR)	Comment	Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)	Bleeding complications requiring more than local measures
Sindet-Pederson et al. 1989 ⁸⁵	39 (39)	119	112	INR 2.5-4.8	Tranexamic acid or placebo mouthwash	10	1 pt required hospitalization and fresh-frozen plasma.
Souto et al. 1996 ⁸⁶	153 (156)	≥ 153 ≤ 163	≥ 153 ≤ 163	INR 1.5-5.25	tranexamic acid mouthwash for some pts	7	INR not reported 0 (Souto JC, Fontcuberta J. Personal correspondence. August 21, 1996.)
Street & Leung 1990 ⁸⁷	12 (12)	12	12	INR not reported	Tranexamic acid mouthwash	1	0 although 1 pt not compliant with mouthwash who had an impacted infected tooth extraction was admitted to the hospital for observation but not treatment
Svensson et al. 2013 ⁸⁸	124 (124)	194	194	Mean INR 2.4 (1.0-3.5)		5	0
Thronsdon & Walstad 1999 ⁸⁹	1 (1)	1	1	3.8	Tranexamic mouthwash postoperatively	1	1 transfusion and argon beam coagulator
Tomasi & Wolf 1974 ⁹⁰	1 (1)	2	1	PT ratio 1.2		0	0
Tulloch & Wright 1954 ⁹¹	1 (1-2)	1?	1?	PT ratio 3.3		0	0
Waldrep & McKelvey 1968 ⁹²	20 (20)	76	60	Prothrombin activity rate 30% or less; average 20.3% [INR 2.5 or more; average INR 3.0]		3	2 pts had postop anticoagulation withdrawn to control postop bleeding

(continued on next page)

Table I. Continued

<i>Source</i>	<i>No. of patients (pts) treated (visits)</i>	<i>No. of surgical procedures</i>	<i>No. of extractions</i>	<i>International normalized ratio (INR)</i>	<i>Comment</i>	<i>Postoperative bleeding that required professional treatment at least with local measures (other than immediately postoperatively)</i>	<i>Bleeding complications requiring more than local measures</i>
Wood & Deeble 1993 ⁹³	2 (2)	7	7	INR 2.3-2.9 preop; INR 4.3-9.1 postop	Sutures and surgical	2	2: After bleeding control with local measures, 1 pt (preop INR 2.3) bled 2 days after extraction when his INR was 4.3, possibly from interaction with concomitant erythromycin. Given fresh frozen plasma and blood. 1 pt (preop INR 2.9 for 6 extractions) no bleeding problem until 1 week later (oozing from one socket) when INR was 9.1. Given fresh frozen plasma, blood, and vitamin K.
Yoshimura et al. 1987 ⁹⁴	13-16 (19)	19	19	PT ratio 1.05-2.1 when reported		6	0
Zanon et al. 2003 ⁹⁵	250 (250)	525	525	1.8-4.0	236 extractions surgical	4	0
Ziffer et al. 1957 ¹	2 (3)	3	3	PT ratio 2.35 to 2.8		2	2 (3 episodes: PT ratio 2.8 for one pt; PT ratio 2.35 and 2.4 for other pt): vitamin K administered
Zusman et al. 1992 ⁹⁶	23 (23)	61	61	PT 50% to 19% [INR <2.0 to INR 3.2]		3	0
TOTALS	>5431 (>5677)	>11,381	>10,322			375 (7% of pts and visits)	31 (0.6% of pts, 0.5% of visits)

Table II. Anticoagulation interruption for dental procedures

<i>Source</i>	<i>No. of patients (pts)</i>	<i>No. of interruptions for dental procedures</i>	<i>Presurgical days of cessation or reduction</i>	<i>International normalized ratio (INR) after withdrawal</i>	<i>Bleeding complications treated with local measures by doctor</i>	<i>Thromboembolic complications</i>
Akbarian et al. 1968 ⁹⁷	1	1	Not reported	Not reported	0	1 fatal embolism
Akopov et al. 2005 ⁹⁸	2	2	4-6	Not reported	Not reported	2: 1 pt withdrawn for 4 days before dental procedure; 1 pt withdrawn for 3 days before cataract surgery and did not restart for the upcoming dental procedure On the 6th day after withdrawal, a cerebral infarction developed
Al-Mubarak et al. 2006, ¹⁷ 2007 ¹⁸	104	104	2	Mean 1.8-9	7 had postoperative bleeding on day 3	0
Aldous and Olson 2001 ⁹⁹	1	1	Warfarin withdrawn for 2 days and replaced with heparin	Preop INR not reported, but on postop day 15 INR was 3.5 and on day 18 it was INR 13	1 on postop day 15 and eventually on day 18, when INR was 13, transfusion and vitamin K given	0
Alexander R 2003 ¹⁰⁰	4	4	1-5	Not reported	Not reported	4; 2 fatal
Anavi 1981 ²⁰	15	15	until prothrombin time (PT) level was 50%-60%		3	0
Bajkin et al. 2009 ²⁵	105	105	Warfarin or acenocoumarol withdrawn 3-4 days (with low-molecular-weight heparin [LMWH] nadroparin-calcium replacement) until INR <1.5	INR 1.06-1.47 (mean 1.26)	3	0
Baykul et al. 2010 ¹⁰¹	2	2	INR reduced, but not reported how	1.3-1.4	1	0
Behrman & Wright 1961 ³¹	1	1	Anticoagulation withdrawn before dental surgery (number of days unreported)	Not reported	0	1 fatal massive cerebral thrombosis 17 days after discontinuing warfarin
Behrman and Wright 1961 ³¹	4	4	Warfarin withdrawn day of surgery or 1 day preoperatively	Not reported	1	0

(continued on next page)

Table II. Continued

<i>Source</i>	<i>No. of patients (pts)</i>	<i>No. of interruptions for dental procedures</i>	<i>Presurgical days of cessation or reduction</i>	<i>International normalized ratio (INR) after withdrawal</i>	<i>Bleeding complications treated with local measures by doctor</i>	<i>Thromboembolic complications</i>
Bloomer 2004 ¹⁰²	1	1	5 (with enoxaparin substitution but no anticoagulation at all for 12 hours)	1.5 one day before surgery	1 (vitamin K administered also)	0
Borea et al. 1993 ³⁵	15	15	Anticoagulation withdrawn or reduced in artificial heart valve patients	Preop INR 1.5-2.5 (mean 1.69) in artificial heart valve patients	2	0
Broderick et al. 2011 ¹⁰³	1	1	Not reported	Not reported	Not reported	1 after warfarin cessation for a dental procedure
Brooks 2011 ³⁶	1	1	14 (with enoxaparin substitution)	1.2 (1.4 at hospital admission)	1 (fresh frozen plasma transfusion)	0
Campbell et al. 2000 ³⁷	13	13	3-4	1.1-3.0 (mean 2.0)	0	0
Cannon & Dharmar 2003 ⁴⁰	32	32	2-4	<2.0	2	0
Crean et al. 2000 ¹⁰⁴	1	1	3 (with heparin substitution on the 3rd day)	1.3	0	0
Davies D 2003 ⁴⁸	1	1	2 (anticoagulant reduced)	Not reported	0	1 transient ischemic attack (TIA)
Davis & Sczupak 1979 ¹⁰⁵	28	28?	Up to 2 weeks for “dental or surgical procedures”	Not reported	Not reported	0
Della Valle et al. 2003 ¹⁰⁶	40	40	1.5	1.5-3.0	17	0
Devani et al. 1998 ⁴⁹	32	32	Warfarin withdrawn 2 days preoperatively until INR 1.5-2.1	INR 1.2-2.1 (mean 1.6)	1	0
Douketis et al. 2004 ¹⁰⁷	3	3	5-6 days (LMWH dalteparin replacement); stop dalteparin at least 12 hr before surgery	Not reported	0 (but rectus sheath hematoma)	0
Dunn et al. 2007 ¹⁰⁸	22	≥22	5 days (LMWH enoxaparin replacement; stop enoxaparin day of procedure)	<1.8	0	0
Elad & Findler 2008 ⁵¹	2	2	Not reported; warfarin replaced with LMWH	Not reported	2	0
Evans et al. 2002 ⁵³	52	52	2	1.2-2.3 (mean 1.6)	0	0
Finn & Schow 1993 ¹⁰⁹	1	1	4 (with heparin substitution)	PT 12.8 seconds (INR not reported)	0	0
Garcia et al. 2008 ¹¹⁰	257	323	1-10 in larger study	Not reported	Not reported	1 after a 7 day interruption for oral surgery
Gaspar et al. 1997 ⁵⁷	15	15	Warfarin withdrawn for 3 days	INR 1.25-1.9 (mean 1.45)	1	0

(continued on next page)

Table II. Continued

<i>Source</i>	<i>No. of patients (pts)</i>	<i>No. of interruptions for dental procedures</i>	<i>Presurgical days of cessation or reduction</i>	<i>International normalized ratio (INR) after withdrawal</i>	<i>Bleeding complications treated with local measures by doctor</i>	<i>Thromboembolic complications</i>
Giuffrè et al. 2006 ⁵⁸	52	52	Until PT, partial thromboplastin time (PTT), and INR values reached 50% (heparin replacement)	1.0-1.75	0	0
Hadziabdic et al. 2011 ⁶¹	21	21	For 1 day, anticoagulation reduced in 4 and withdrawn in 17 patients	Not reported	0	0
Johnson-Leong & Rada 2002 ¹¹¹	1	1	4 (with enoxaparin substitution but no anticoagulation at all for 24 hours)	1.1	0	0
Karsli et al. 2011 ⁶⁵	21	26	3 days with LMWH or unfractionated heparin (UFH) bridging	Mean 1.6	0	0
Lund et al. 2002 ¹¹²	6	≥6	Heparin replacement to reach PTT 55-65 seconds (all patients were on mechanical circulatory support)	Not reported	3 patients had minor hemorrhage 4 days after surgery	2 transient ischemic events
Marshall 1963 ¹¹³	1	1	Anticoagulation withdrawn 9 days preoperatively	Not reported	0	1 fatal myocardial infarction 19 days after interruption of therapy of 9 days duration
Mehra et al. 2000 ¹¹⁴	20	20	1-2 days with heparin replacement	Not reported	1	0
Milligan et al. 2003 ¹¹⁵	≥1	1	4 to 5	1.2-1.8 (mean INR 1.5 for entire study, which included nondental surgeries)	Not reported	0
Morimoto et al. 2008 ⁷¹	4	7	2 days warfarin reduction with LMWH (dalteparin) replacement	1.2-2.36	1 (compression and warfarin discontinuation 6 days postop due to high INR and oozing)	0
Mulligan 1987 ¹¹⁶	17	44	Anticoagulation withdrawn 2-7 days preoperatively	PTR 1.13-1.93	0	0
Nakasato et al. 1989 ⁷⁴	28	28	Warfarin discontinued until thrombin test level raised from 40%-50%	Mean thrombin test value 49.8% ± 14.5%	0	0

(continued on next page)

Table II. Continued

<i>Source</i>	<i>No. of patients (pts)</i>	<i>No. of interruptions for dental procedures</i>	<i>Presurgical days of cessation or reduction</i>	<i>International normalized ratio (INR) after withdrawal</i>	<i>Bleeding complications treated with local measures by doctor</i>	<i>Thromboembolic complications</i>
Ogiuchi et al. 1985 ¹¹⁷	128	128	Warfarin dose decreased 3 to 7 days preoperatively, then discontinued the day of the procedure and restarted afterward	Thrombotest values 10%-100%	0	1 fatal cerebral thromboembolism 5 days postoperatively.
Pávek & Bigl 1993 ¹¹⁸	11	11	Anticoagulation reduced for one day and then withdrawn for 1 day with heparin replacement	≤1.87	0	0
Pearce et al. 1975 ¹¹⁸	1	1	Warfarin withdrawn for unknown days	Not reported	0	0
Prudoff & Stratigos 1972 ¹²⁰	2	2	Warfarin withdrawn 2 days preoperatively	Protime 13/13 and 22/14	0	0
Roberts 1961 ¹²¹	3	3	3-4	PT 25-33 seconds; 24; 21	1 after 2 days of postoperative bleeding, intravenous estrogen was administered for hemostasis	0
Roberts 1966 ¹²²	≥40	≥40	3 days	PT up to 25 seconds	0	0
Russo et al. 2000 ¹²³	104	104	2	1.18-3.4 (mean INR 1.87)	2	0
Sacco et al. 2007 ⁷⁹	66	66	3 (dosages reduced until for target INR 1.8)	Mean 1.77	10	0
Sammartino et al. 2012 ⁸²	31	≥31	Warfarin withdrawn "some days" before procedure until INR <2.0	Preop INR <2.0	4 treated with local measures 2-4 days postoperatively	0
Saour et al. 1994 ¹²⁴	212	212	Warfarin withdrawn 2 days or until INR ≤1.5	INR ≤1.5	0	0
Scheitler et al. 1988 ¹²⁵	1	1	1 day; heparin replacement until 6 hours before surgery	PT 13.0/10.2 seconds	0	0
Schofield 1984 ¹²⁶	~ 168	~ 168	Warfarin withdrawn 6 days pre-operatively	Thrombotest >25%	0	0
Sheller & Tong 1994 ¹²⁷	1	1	Warfarin withdrawn for 2 days	Not reported	0	0
Somma et al. 2010 ¹²⁸	80	≥80	3 days	Not reported	0	2 thromboembolic complications
Somma et al. 2010 ¹²⁸	800	≥800	Warfarin dosage adjusted	1.6-1.8	82	0
Souto et al. 1996 ⁸⁶	39	39	Anticoagulation reduced for 2 days and replaced with heparin	INR 1.25-5.0	13	0

(continued on next page)

Table II. Continued

<i>Source</i>	<i>No. of patients (pts)</i>	<i>No. of interruptions for dental procedures</i>	<i>Presurgical days of cessation or reduction</i>	<i>International normalized ratio (INR) after withdrawal</i>	<i>Bleeding complications treated with local measures by doctor</i>	<i>Thromboembolic complications</i>
Street & Leung 1990 ⁸⁷	2	2	Not reported	Not reported	0	0
Todd 2001 ¹²⁹	1	1	Anticoagulant withdrawn until INR normalized	Not reported	0	0
Tulloch & Wright 1954 ⁹¹	12	13	Anticoagulant withdrawn for 4 days in most cases	Not reported	0	1 pt whose therapy was withdrawn for 8 days developed cerebral and brachial nonfatal emboli
Wilson et al. 2001 ¹³⁰	6	6	Warfarin discontinued 5 days before procedure with LMWH (dalteparin) substitution	≤1.5	1	0
Wood & Conn 1954 ¹³¹	5	5	Anticoagulation withdrawn "dental extraction or surgical procedure" 7 to 37 days	Not reported	0	0
Yasaka et al. 2006 ¹³²	4	4	3-6	0.94-2.5 on admission	Not reported	4 cardioembolic strokes: Interrupted at 3, 4, 5, and 6 days before dental extractions
Yoshimura et al. 1987 ⁹⁴	4	4	Anticoagulant withdrawn or reduced 1-2 days preoperatively	Not reported	0	0
Ziffer et al. 1957 ¹	1	1	9 days		0	0
Zusman et al. 1993 ⁹⁶	23	23	2	Not reported	0	0
TOTALS	≥2673	≥2775			161 (6% of pts and visits), including 5 (0.2%) administered more than local measures	15 (0.6% of pts, 0.5% of visits); 6 (0.2% of pts or visits) fatal

Analysis of some cases of embolic complications after anticoagulation withdrawal or reduction for dental procedures

Alexander reported four cases of catastrophic embolic complications in patients whose anticoagulation was withdrawn before dental extractions after the dentists consulted with physicians. Two cases were fatal, and all four ended in lawsuits—presumably both the dentist and physician were sued for inappropriately recommending anticoagulation interruption without good reason in each of these cases.¹⁰⁰ In one case, the plan was to substitute low-molecular-weight heparin (LMWH) for warfarin once the INR level fell below 2.0 in a patient with anticardiolipin, but the patient suffered a fatal pulmonary embolism after warfarin withdrawal and before LMWH could be started. In another case of a patient with atrial fibrillation, the dentist consulted with the patient's cardiologist before a single extraction. The cardiologist recommended a 3- to 5-day withdrawal of warfarin. On day 4 of warfarin interruption, the extraction was done, and that evening the patient suffered a fatal pulmonary embolism. In the other two cases, the patients' physicians recommended interruption of warfarin for single extractions. After INR levels fell below 2.0, both patients suffered major strokes.

Akopov et al. reported thrombotic events in five patients with INR between 1.5 and 2.0 at hospital admission after anticoagulation withdrawal for medical procedures.⁹⁸ Two of these patients were dental patients, one whose anticoagulation was withdrawn for 4 days preoperatively and the other whose anticoagulation was withdrawn for 3 days before cataract surgery; however, anticoagulation was not immediately restarted due to an upcoming dental appointment. On postoperative day 6, the second patient suffered a cerebral infarct. The authors noted that withdrawal of warfarin for dental procedures was based on a "mostly theoretical risk of hemorrhage...which may be controlled with local measures should it occur at all." They concluded, "[T]emporary discontinuation of warfarin for invasive procedures in patients with established high-risk for cardioembolic cerebral infarction may lead to a devastating cerebral infarction. These events constitute an unacceptably large percentage of hospital admissions for cardioembolic cerebral infarctions."

Garcia et al. studied 1293 cases of warfarin interruption in 1024 patients, including 323 warfarin interruptions in 257 oral or dental surgery patients.¹¹⁰ Only 8.3% of warfarin interruptions included patients receiving bridge therapy with heparin, and this bridge therapy was associated with a higher risk of postoperative hemorrhage compared with no bridge therapy. Interestingly, of all 1293 cases of mostly nondental surgical procedures, 23 patients whose warfarin was interrupted (of whom 14

were on periprocedural heparin bridge therapy) sustained major or significant hemorrhage after the procedure anyway. Overall, there were 7 thromboembolic events (none in patients receiving bridge therapy), including a stroke suffered by a dental patient whose warfarin was withdrawn for 7 days for a dental procedure.

Of the 2197 cases of ischemic stroke identified through hospital discharge records, Broderick et al. determined that 114 (5.2%) occurred within 60 days of antithrombotic agent withdrawal, about half of which were withdrawn by a physician in the periprocedural period.¹⁰³ One of the cases of stroke was after warfarin cessation for a dental procedure.

EVALUATION AND DISCUSSION OF THE EVIDENCE

The reviewed literature indicates that withdrawing or reducing therapeutic levels of warfarin for dental procedures is associated with a small but real risk of embolic complications, such as stroke, and pulmonary embolism. Although the risk may be low, embolic complications after warfarin withdrawal for dental surgery can lead to permanent morbidity or even be fatal. On the other hand, there are no documented cases of permanent morbidity or fatalities from bleeding complications when anticoagulation is continued for dental surgery, and most such bleeding complications are easily treated with local hemostatic measures. Although most authorities assert that anticoagulation should be continued for dental surgery, some still recommend anticoagulation withdrawal or reduction, based on one or more of the positions discussed below.

Position 1: Bleeding complications can be disconcerting to patients and dentists

The American College of Chest Physicians (ACCP) states that postoperative bleeding after dental surgery can cause "anxiety and distress."¹³³ Todd stated, "My experience and that of many of my colleagues is that even though bleeding is never life threatening, it can be difficult to control at therapeutic levels of anticoagulation and can be troublesome, especially for elderly patients."¹³⁴ While minor postoperative bleeding can be disconcerting to both patients and dentists, it is also true that postoperative bleeding in anticoagulated dental patients is rare and usually amenable to management with local hemostatic measures. In fact, most studies have shown that minor bleeding complications occur at a rate similar to those in patients whose anticoagulation was withdrawn or reduced for dental surgery.

In our series (Tables I and II), the incidence of minor bleeding in the anticoagulation group (~7%) was about

the same as in the anticoagulation withdrawal group or the reduction group (~6%). Even though the incidence of bleeding requiring more than local measures was higher in the anticoagulation group (0.5% of visits), five patients (0.2% of visits) in the anticoagulation withdrawal or reduction group also required more than local measures to control hemorrhage. On the other hand, embolic complications in dental patients whose anticoagulation is withdrawn or reduced, while also infrequent, can be devastating and even fatal. Surely, after a dental procedure, an embolic complication after anticoagulation withdrawal or reduction is more disconcerting than a bleeding complication when anticoagulation is continued.

Position 2: Embolic complications are rare when anticoagulation is reduced or withdrawn for dental procedures, and those documented cases of embolic complications for dental procedures have very long warfarin cessation periods

In 2010, Balevi stated that recommendations for continuing anticoagulation for dental extractions “were made despite the fact that there has been no reported case of a dental extraction causing a cardiovascular accident (CVA) in a patient whose warfarin was temporarily discontinued.”¹³⁵ In a letter responding to this assertion “Bleed or die? A bloody simple decision,”¹³⁶ it was pointed out that there had been at least five serious embolic complications (one fatal) reported in the literature after warfarin withdrawal for dental procedures.^{31,91,97,113,117} Todd points out that in these five cases of embolic events after warfarin cessation, the cessation period was either unknown or ranged from 5 to 19 days of withdrawal, so he advocates a brief discontinuation of anticoagulation for some oral surgical procedures, partly based on the lack of cases in the literature of thrombotic events in patients whose INR levels fell to 1.5 to 2.0.^{134,137} Russo et al. advocated warfarin interruption for prosthetic valve patients undergoing dental surgery, calling a 2-day interruption “simple and safe.”¹²³

Our current review documenting 22 cases (6 fatal) of embolic complications after anticoagulation, demonstrated that embolic complications have been reported with warfarin interruption for as few as 2, 3, or 4 days (Table II). Yasaka et al. reported cases of cardioembolic stroke in four patients whose warfarin was withdrawn for 3 to 6 days before dental extractions. INR levels in these patients ranged from 0.94 to 2.5 on admission.¹³²

On the other hand, postoperative bleeding complications that require more than local hemostatic measures are rare, and there have been no fatal cases of hemorrhage documented after dental surgery in continuously anticoagulated patients.

The recommended therapeutic INR range for most patients, including patients with mechanical aortic valves is INR levels of 2.0 to 3.0, although the INR level is 2.5 to 3.5 for those with mechanical mitral valves.¹³⁸ There are no patients whose recommended optimal levels are lower than INR 2.0 or higher than INR 3.5. Even a brief interruption of warfarin would reduce the INR to a *suboptimal* level, exposing these patients to a higher risk of stroke or even death for little or no benefit in prevention of postoperative hemorrhage. If postoperative hemorrhage occurs at all, it can usually be treated with local measures. Although embolic events are infrequent when warfarin anticoagulation is briefly interrupted, when an embolic event, such as a stroke, occurs, it is often catastrophic and sometimes fatal.

Position 3: The 2012 ACCP statement provides an option to discontinue anticoagulation for dental procedures

The ACCP consensus statements issued in 2001,¹³⁹ 2004,¹⁴⁰ and 2008¹⁴¹ have recognized that the risk of hemorrhage after dental surgery in anticoagulated patients was outweighed by the morbidity of the risk of embolic complications from reducing or withdrawing anticoagulation and recommended continuing anticoagulation for dental surgery. In 2012,¹³³ the ACCP recommended dental surgery without warfarin interruption and with a prohemostatic mouthwash but gave an additional option to withdraw anticoagulation for 2 to 3 days before the dental procedure, citing four prospective studies as references for this option. None of these studies (discussed below) supports warfarin interruption—on the contrary, they confirm that continuous warfarin is safe and appropriate for dental surgery.

Campbell et al. studied anticoagulated dental surgical patients divided into three groups: (1) 12 patients whose anticoagulation was continued, (2) 13 whose anticoagulation was interrupted for 3 to 4 days before surgery, and (3) an additional control group of patients who had never been on anticoagulant therapy.³⁷ There was no difference in blood loss in any of the groups, and no patient suffered any bleeding complications. The authors concluded, “The data suggest that many patients can safely undergo routine outpatient oral surgical procedures without alteration of their regular therapeutic anticoagulation regimens and without additional medical intervention.” Beirne, in an accompanying discussion, stated that “this study strongly supports the recommendation” for continuing therapeutic anticoagulation before dental extractions.¹⁴²

Devani et al. studied 65 anticoagulated patients undergoing dental extractions,⁴⁹ divided into a control group whose warfarin was interrupted and a study group

whose warfarin was continued. With no bleeding complications requiring more than local hemostatic measures, the authors concluded there is “no justification in altering warfarin treatment (between INR 2.0 and 4.0) before dental extractions in these patients, and thereby exposing them to the risk of thromboembolism.”

Gaspar et al. studied 47 continuously anticoagulated oral surgical patients, divided into two groups.⁵⁷ Anticoagulation was reduced in the control group, and there was no change in the test group. The incidence of bleeding in the two groups was not significantly different, and the authors concluded that “patients taking anticoagulant therapy should not discontinue their medication before ambulatory oral surgery.”

Blinder et al. divided 249 patients undergoing dental extractions into five groups, based on lowest to highest INR levels.³⁴ There was no significant difference in the incidence of postoperative bleeding between the groups, and the INR value did not significantly affect the incidence of postoperative bleeding. No patient required more than local hemostatic measures. The authors concluded that “dental extractions can be performed without modification of oral anticoagulant treatment.”

In each of these cases, there were no bleeding complications that required more than local hemostatic measures whether anticoagulation was reduced, withdrawn, or continued, and in each case the authors concluded that anticoagulation should be continued for dental surgery with local hemostatic measures. Although there were no embolic complications reported in any of these studies, patients were exposed to a life-threatening, although low, risk of embolism with suboptimal levels of anticoagulation without a concomitant decreased risk of hemorrhage, which if it occurred would probably not have been life threatening anyway.

CONCLUSION

Potential bleeding complications in anticoagulated patients undergoing dental surgery must be weighed against possible embolic complications when anticoagulation is withdrawn or reduced for dental surgery. This review of the literature has confirmed earlier findings that there is an exceedingly low risk (0.6%) of bleeding complications that require more than local hemostatic measures in continuously anticoagulated patients, with no cases of permanent morbidity or fatality. On the other hand, there is a similarly low (0.8%) but highly significant risk of serious embolic complications in patients whose anticoagulation is reduced or withdrawn for dental procedures. In some cases, these embolic complications resulted in permanent morbidity and even fatality. The evidence reviewed indicates that therapeutic anticoagulation with warfarin should not be interrupted for most dental surgery.

REFERENCES

- Ziffer AM, Scopp IW, Beck J, Baum J, Berger AR. Profound bleeding after dental extractions during dicumarol therapy. *N Engl J Med.* 1957;256:351-353.
- Doonquah L, Mitchell AD. Oral surgery for patients on anti-coagulant therapy: current thoughts on patient management. *Dent Clin North Am.* 2012;56:25-41.
- Wahl MJ. Dental surgery in anticoagulated patients. *Arch Intern Med.* 1998;158:1610-1616.
- Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. *J Am Dent Assoc.* 2000;131:77-81.
- Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. *Br J Oral Maxillofac Surg.* 2000;38:124-126.
- Little JW, Miller CS, Henry RG, McIntosh BA. Antithrombotic agents: implications in dentistry. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2002;93:544-551.
- Aframian DJ, Lalla RV, Peterson DE. Management of dental patients taking common hemostasis-altering medications. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;103:S45. e1-e11.
- Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. *Arch Intern Med.* 2003;163:901-908.
- Malden N. Dental procedures can be undertaken without alteration of oral anticoagulant. *Evid Based Dent.* 2005;6:11.
- Nematullah A, Allabousi A, Blanas N, et al. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. *J Can Dent Assoc.* 2009;75:41a-i.
- Aldridge E, Cunningham LL. Current thoughts on treatment of patients receiving anticoagulation therapy. *J Oral Maxillofac Surg.* 2010;68:2879-2887.
- Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. *J Am Dent Assoc.* 2003;134:1492-1497.
- Beirne OR. Evidence to continue oral anticoagulant therapy for ambulatory oral surgery. *J Oral Maxillofac Surg.* 2005;63:540-545.
- Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2012;113:431-441.
- Al Zoman H, Al Jetaiy S, Robert AA, et al. Flapless dental implant surgery for patients on oral anticoagulants – the “WarLess Procedure”: a report of 2 cases. *J Oral Implantol.* 2013;39(Spec Issue):264-270.
- Al-Belasy FA, Amer MZ. Hemostatic effect of n-butyl-2-cyanoacrylate (histoacryl) glue in warfarin-treated patients undergoing oral surgery. *J Oral Maxillofac Surg.* 2003;61:1405-1409.
- Al-Mubarak S, Rass MA, Alsuwied A, et al. Thromboembolic risk and bleeding in patients maintaining or stopping oral anticoagulant therapy during dental extraction. *J Thromb Haemost.* 2006;4:689-691.
- Al-Mubarak S, Al-Ali N, Abou Rass M, et al. Evaluation of dental extractions, suturing and INR on post-operative bleeding of patients maintained on oral anticoagulant therapy. *Br Dent J.* 2007;203:E15.
- Alexander R, Ferretti AC, Sorensen JR. Stop the nonsense not the anticoagulants: a matter of life and death. *NY State Dent J.* 2002;68:24-26.
- Anavi Y, Sharon A, Gutman D, Laufer D. Dental extractions during anticoagulant therapy. *Isr J Dent Med.* 1981;28:9-12.
- Askey JM, Cherry CB. Dental extraction during dicumarol therapy. *Calif Med.* 1956;84:16-17.

22. Bacci C, Maglione M, Favero L, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicenter, prospective, case-control study. *Thromb Haemost.* 2010;104:972-975.
23. Bacci C, Berengo M, Favero L, Zanon E. Safety of dental implant surgery in patients undergoing anticoagulation therapy: a prospective case-control study. *Clin Oral Implants Res.* 2011;22:151-156.
24. Bailey BMW, Fordyce AM. Complications of dental extractions in patients receiving warfarin anticoagulant therapy: a controlled clinical trial. *Br Dent J.* 1983;155:308-310.
25. Bajkin BJ, Popovic SL, Selakovic SDJ. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. *J Oral Maxillofac Surg.* 2009;67:990-995.
26. Bajkin BV, Bajkin IA, Petrovic BB. The effects of combined oral anticoagulant-aspirin therapy in patients undergoing tooth extractions: a prospective study. *J Am Dent Assoc.* 2012;143:771-776.
27. Bakathir AA. Minor oral surgery procedures in patients taking warfarin: a 5-year retrospective study at Sultan Qaboos University Hospital, Sultanate of Oman. *Sultan Qaboos Univ Med J.* 2009;9:279-286.
28. Bal BJ, Hardee PS. Efficacy and cost effectiveness of tranexamic acid mouthrinse for oral surgery in warfarinized patients [abstract]. *Br J Oral Maxillofac Surg.* 2000;38:390.
29. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1996;82:610-612.
30. Barrero MV, Knezevic M, Martín MT, et al. Oral surgery in patients undergoing oral anticoagulant therapy. *Med Oral.* 2002;7:63-70.
31. Behrman SJ, Wright IS. Dental surgery during continuous anticoagulant therapy. *J Am Dent Assoc.* 1961;62:172-180.
32. Benoliel R, Leviner E, Katz J, Tzukert A. Dental treatment for the patient on anticoagulant therapy: prothrombin time value — what difference does it make? *Oral Surg Oral Med Oral Pathol.* 1986;62:149-151.
33. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on continued oral anticoagulant: comparison of local hemostatic modalities. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1999;88:137-140.
34. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of post-operative bleeding. *Int J Oral Maxillofac Surg.* 2001;30:518-521.
35. Borea G, Montebugnoli L, Capuzzi P, Magelli C. Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery: an alternative method to discontinuing anticoagulant therapy. *Oral Surg Oral Med Oral Pathol.* 1993;75:29-31.
36. Brooks AS. Delayed complications of tooth extractions in patients taking warfarin, antibiotics, and other medications. *J Oral Maxillofac Surg.* 2011;69:977-979.
37. Campbell JH, Alvarado F, Murray RA. Anticoagulation and minor oral surgery: should the anticoagulation regimen be altered? *J Oral Maxillofac Surg.* 2000;58:131-135.
38. Candemir B, Güleç S, Özdemir AO, Kumbasar D. Very late drug-eluting stent thrombosis in a patient with an INR of 4.4. *Arch Turk Soc Cardiol.* 2010;38:561-563.
39. Cañigral A, Silvestre F-J, Cañigral G, et al. Evaluation of bleeding risk and measurement methods in dental patients. *Med Oral Pathol Oral Cir Bucal.* 2010;15:e863-e868.
40. Cannon PD, Dharmar VT. Minor oral surgical procedures in patients on oral anticoagulants—a controlled study. *Aust Dent J.* 2003;48:115-118.
41. Carter G, Goss A. Tranexamic acid mouthwash—a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent post-operative bleeding in anticoagulated patients requiring dental extractions. *Int J Oral Maxillofac Surg.* 2003;32:504-507.
42. Carter G, Goss AN, Lloyd J, Tocchetti R. Local haemostasis with autologous fibrin glue following surgical enucleation of a large cystic lesion in a therapeutically anticoagulated patient. *Br J Oral Maxillofac Surg.* 2003;41:275-276.
43. Carter G, Goss A, Lloyd J, et al. Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. *J Oral Maxillofac Surg.* 2003;61:1432-1435.
44. Cesar JM, Iturriaga TM. Correction by desmopressin of bleeding following dental extraction in a patient under antithrombotic therapy [letter]. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2007;104:151.
45. Cieślík-Bielecka A, Pelc R, Cieślík T. Oral surgery procedures in patients on anticoagulants. Preliminary report. *Kardiol Pol.* 2005;63:137-140.
46. Cone A. Dental abscess in an anticoagulated patient with ankylosing spondylitis. *Br J Hosp Med.* 1993;49:190.
47. Dantas AK, Deboni MC, Peratininga JL. Dental surgery in patients on oral anticoagulation therapy. *Rev Bras Hematol Hemoter.* 2009;31:337-340.
48. Davies D. Minor oral surgical procedures in patients on oral anticoagulants [letter]. *Aust Dent J.* 2003;48:267.
49. Devani P, Lavery M, Howell CJT. Dental extractions in patients on warfarin: is alteration of anticoagulation regime necessary? *Br J Oral Maxillofac Surg.* 1998;36:107-111.
50. Eichhorn W, Burkert J, Vorwig O, et al. Bleeding incidence after oral surgery with continued oral anticoagulation. *Clin Oral Investig.* 2012;16:1371-1376.
51. Elad S, Findler M. Periodontal surgery for patients receiving anticoagulant therapy [letter]. *Arch Intern Med.* 2008;168:1719.
52. Elad S, Zadik Y, Kaufman E, et al. A new management approach for dental treatment after a cerebrovascular event: a comparative retrospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2010;110:145-150.
53. Evans IL, Sayers MS, Gibbons AJ, et al. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. *Br J Oral Maxillofac Surg.* 2002;40:248-252.
54. Ferrieri GB, Castiglioni S, Carmagnola D, et al. Oral surgery in patients on anticoagulant treatment without therapy interruption. *J Oral Maxillofac Surg.* 2007;65:1149-1154.
55. Frank BW, Dickhaus DW, Claus EC. Dental extractions in the presence of continual anticoagulant therapy. *Ann Intern Med.* 1963;59:911-913.
56. Gagneja M, Gagneja P, Steelman R, Shaughnessy R, Johannes PW. Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism. *J Clin Pediatr Dent.* 2007;32:151-154.
57. Gaspar R, Brenner B, Ardekian L, Peled M. Use of tranexamic acid mouthwash to prevent post-operative bleeding in oral surgery patients on oral anticoagulant medication. *Quintessence Int.* 1997;28:375-379.
58. Giuffrè G, Caputo G, Misso S, Peluso F. Platelet-rich plasma treatment and hemostasis in patients with hemorrhagic risk. *Minerva Stomatol.* 2006;55:599-609.
59. Goodchild JH, Donaldson M. A clinically significant drug interaction between warfarin and amoxicillin resulting in persistent post-operative bleeding in a dental patient. *Gen Dent.* 2013;61:50-54.

60. Greenberg MS, Miller MF, Lynch MA. Partial thromboplastin time as a predictor of blood loss in oral surgery patients receiving coumarin anticoagulants. *J Am Dent Assoc.* 1972;84:583-587.
61. Hadziabdic N, Sulejmanagic H, Haracic M, et al. Recommended INR values for performing oral-surgical interventions. *HealthMED.* 2011;5:2243-2251.
62. Halfpenny W, Fraser JS, Adlam DM. Comparison of 2 hemostatic agents for the prevention of postextraction hemorrhage in patients on anticoagulants. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2001;92:257-259.
63. Hong C, Napenas JJ, Brennan M, et al. Risk of post-operative bleeding after dental procedures in patients on warfarin: a retrospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2012;114:464-468.
64. Inchingolo F, Tatullo M, Abenavoli FM, et al. Odontostomatologic management of patients receiving oral anticoagulant therapy: a retrospective multicentric study. *Ann Surg Innov Res.* 2011;5:1-5.
65. Karsli ED, Erdogan O, Esen E, Acartürk E. Comparison of the effects of warfarin and heparin on bleeding caused by dental extraction: a clinical study. *J Oral Maxillofac Surg.* 2011;69:2500-2507.
66. Kovács B, Tóth K, Kerényi G. Post-extraction hemostasis during coumarin anticoagulant therapy with a locally applied coagulation-active substance. *Int J Oral Surg.* 1976;5:3-7.
67. Kusafuka Y, Kurita H, Sakurai S, et al. Effect of single-dose extended-release oral azithromycin on anticoagulation status in warfarinized patients. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2013;115:148-151.
68. Kwapis BW. Anticoagulant therapy and dental practice. *J Am Dent Assoc.* 1963;66:172-175.
69. Martinowitz U, Mazar AL, Taicher S, et al. Dental extraction for patients on oral anticoagulant therapy. *Oral Surg Oral Med Oral Pathol.* 1990;70:274-277.
70. McIntyre H. Management, during dental surgery of patients on anticoagulants. *Lancet.* 1966;2:99-100.
71. Morimoto Y, Niwa H, Minematsu K. Hemostatic management of tooth extractions in patients on oral antithrombotic therapy. *J Oral Maxillofac Surg.* 2008;66:51-57.
72. Morimoto Y, Niwa H, Minematsu K. Risk factors affecting post-operative hemorrhage after tooth extraction in patients receiving oral antithrombotic therapy. *J Oral Maxillofac Surg.* 2011;69:1550-1556.
73. Morimoto Y, Niwa H, Minematsu K. Hemostatic management for periodontal treatments in patients on oral antithrombotic therapy: a retrospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2009;108:889-896.
74. Nakasato S, Okamura S, Osaka H, et al. Management of dental surgery problems for outpatients with cardiovascular diseases. *Anesth Prog.* 1989;36:140-149.
75. Pereira CM, Gasparetto PF, Santos Carneiro D, et al. Tooth extraction in patients on oral anticoagulants: prospective study conducted in 108 Brazilian patients. *ISRN Dent.* 2011;2011:203619.
76. Raborn GW, Hohn FI, Grace MGA, Arora BK. Tisseel, a two component fibrin tissue sealant system: report of a trial involving anticoagulated dental patients. *J Can Dent Assoc.* 1990;56:779-781.
77. Ramli R, Rahman RA. Minor oral surgery in anticoagulated patients: local measures alone are sufficient for haemostasis. *Singapore Dent J.* 2005;27:13-16.
78. Ramstrom G, Sindet-Pedersen S, Hall G, Blomback M, Alander U. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anti-coagulants. *J Oral Maxillofac Surg.* 1993;51:1211-1216.
79. Sacco R, Sacco M, Carpenedo M, Mannucci PM. Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different intensity targets. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;104:e18-e21.
80. Salam S, Yusuf H, Milosevic A. Bleeding after dental extractions in patients taking warfarin. *Br J Oral Maxillofac Surg.* 2007;45:463-466.
81. Sammartino G, Ehrenfest DMD, Carile F, Tia M, Bucci P. Prevention of hemorrhagic complications after dental extractions into open heart surgery patients under anticoagulant therapy: the use of leukocyte- and platelet-rich fibrin. *J Oral Implantol.* 2011;37:681-690.
82. Sammartino G, Maenzi G, Miro A, et al. Local delivery of the hemostatic agent tranexamic acid in chronically anticoagulated patients. *J Craniofac Surg.* 2012;23:e648-e652.
83. Schmitt J, Ingram RC, Harpole HJ. Hematoma following dental extractions in a patient receiving unreported anticoagulant therapy. *Oral Surg Oral Med Oral Pathol.* 1960;13:791-794.
84. Shira RB, Hall RJ, Guernsey LH. Minor oral surgery during prolonged anticoagulant therapy. *J Oral Surg.* 1962;20:93-99.
85. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. *N Engl J Med.* 1989;320:840-843.
86. Souto JC, Oliver A, Zuazu-Jausoro I, Vives A, Fontcuberta J. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. *J Oral Maxillofac Surg.* 1996;54:27-32.
87. Street AM, Leung W. Use of tranexamic acid mouthwash in dental procedures in patients taking oral anticoagulants. *Med J Aust.* 1990;153:630.
88. Svensson R, Hallmer F, Engleson CS, Svensson PJ, Becktor JP. Treatment with local hemostatic agents and primary closure after tooth extraction in warfarin treated patients. *Swed Dent J.* 2013;37:71-77.
89. Thronson RR, Walstad WR. Use of the argon beam coagulator for control of post-operative hemorrhage in an anticoagulated patient. *J Oral Maxillofac Surg.* 1999;57:1367-1369.
90. Tomasi NJ, Wolf JE. Presurgical management of a patient receiving anticoagulant therapy: report of case. *J Am Dent Assoc.* 1974;88:1028-1029.
91. Tulloch J, Wright IS. Long-term anticoagulant therapy: further experiences. *Circulation.* 1954;9:823-834.
92. Waldrep AC, McKelvey LE. Oral surgery for patients on anticoagulant therapy. *J Oral Surg.* 1968;26:374-380.
93. Wood GD, Deeble T. Warfarin: dangers with antibiotics. *Dent Update.* 1993;20:350-353.
94. Yoshimura Y, Oka M, Kishimoto H, Matsuura R, Mishima K. Hemodynamic changes during dental extraction and post-extraction bleeding in patients with prosthetic heart valves. *Int J Oral Maxillofac Surg.* 1987;16:425-431.
95. Zanon E, Martinelli F, Bacci C, et al. Safety of dental extraction among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. *Blood Coagul Fibrinolysis.* 2003;14:27-30.
96. Zusman SP, Lustig JP, Nun GB. Cost evaluation of two methods of post tooth extraction hemostasis in patients on anticoagulant therapy. *Comm Dent Health.* 1993;10:167-173.
97. Akbarian M, Austen WG, Yurchak PM, Scannell JG. Thromboembolic complications of prosthetic cardiac valves. *Circulation.* 1968;37:826-831.

98. Akopov SE, Suzuki S, Fredieu A, et al. Withdrawal of warfarin before a surgical procedure: time to follow the guidelines? *Cerebrovasc Dis.* 2005;19:337-342.
99. Aldous JA, Olson CJ. Managing patients on warfarin therapy: a case report. *Spec Care Dentist.* 2001;21:109-112.
100. Alexander R. More nonsense. *NY State Dent J.* 2003;69:11.
101. Baykul T, Alanoglu EG, Kocer G. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience. *J Contemp Dent Pract.* 2010;11:1-7.
102. Bloomer CR. Excessive hemorrhage after dental extractions using low-molecular-weight heparin (Lovenox) anticoagulation therapy. *J Oral Maxillofac Surg.* 2004;62:101-103.
103. Broderick JP, Bonomo JB, Kissela BM, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. *Stroke.* 2011;42:2509-2514.
104. Crean SJ, Sivarajasingam V, Muhammed J, Sharma V, Fardy M. Thrombophilia and dental surgery: a report of dental extraction in a patient with protein S deficiency. *Dent Update.* 2000;27:302-305.
105. Davis FB, Sczupak CA. Outpatient oral anticoagulation: guidelines for long-term management. *Postgrad Med.* 1979;66:100-109.
106. Della Valle A, Sammartino G, Marenzi G, et al. Prevention of post-operative bleeding in anticoagulated patients undergoing oral surgery: use of platelet-rich plasma gel. *J Oral Maxillofac Surg.* 2003;61:1275-1278.
107. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. *JAMA Intern Med.* 2004;164:1319-1326.
108. Dunn AS, Spyropoulos AC, Turpie AGG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). *J Thromb Haemost.* 2007;5:2211-2218.
109. Finn MD, Schow SR. Surgical management of a protein S-deficient patient. *J Oral Maxillofac Surg.* 1993;51:181-183.
110. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. *Arch Intern Med.* 2008;168:63-69.
111. Johnson-Leong C, Rada RE. The use of low-molecular-weight heparins in outpatient oral surgery for patients receiving anticoagulation therapy. *J Am Dent Assoc.* 2002;133:1083-1087.
112. Lund J-P, Drews T, Hetzer R, Reichart PA. Oral surgical management of patients with mechanical circulatory support. *Int J Oral Maxillofac Surg.* 2002;31:629-633.
113. Marshall J. Rebound phenomena after anticoagulant therapy in cerebrovascular disease. *Circulation.* 1963;28:329-332.
114. Mehra P, Cottrell DA, Bestgen SC, Booth DF. Management of heparin therapy in the high-risk, chronically anticoagulated, oral surgery patient: a review and a proposed nomogram. *J Oral Maxillofac Surg.* 2000;58:198-202.
115. Milligan PE, Banet GA, Gage BF. Perioperative reduction of the warfarin dose [letter]. *Am J Med.* 2003;115:741-742.
116. Mulligan R. Response to anticoagulant withdrawal. *J Am Dent Assoc.* 1987;115:435-438.
117. Ogiuchi H, Ando T, Tanaka M, et al. Clinical reports on dental extraction from patients undergoing oral anticoagulant therapy. *Bull Tokyo Dent Coll.* 1985;26:205-212.
118. Pávek V, Bigl P. Stomatological treatment of patients with artificial heart valves: coagulation control and antibiotic cover. *Int Dent J.* 1993;43:59-61.
119. Pearce RL, Summers L, Herrmann RP. The management of patients with the Kasabach-Merritt Syndrome. *Br J Oral Surg.* 1975;13:188-195.
120. Prudoff SH, Stratigos GT. Successful management of patients with cardiac valvular prostheses. *NY State Dent J.* 1972;38:207-210.
121. Roberts HJ. Control of bleeding after dental extraction during anticoagulation therapy: with particular reference to estrogenic prophylaxis. *J Am Med Assoc.* 1961;175:962-966.
122. Roberts HJ. Anticoagulants during dental surgery. *Lancet.* 1966;288:639.
123. Russo G, Corso LD, Biasolo A, et al. Simple and safe method to prepare patients with prosthetic heart valves for surgical dental procedures. *Clin Appl Thromb Hemost.* 2000;6:90-93.
124. Saour JN, Ali HA, Mammo LARF, Sieck JO. Dental procedures in patients receiving oral anticoagulation therapy. *J Heart Valve Dis.* 1994;3:315-317.
125. Scheitler LE, Hart N, Phillips G, Weinberg JB. Hematologic and surgical management of the dental patient with plasminogen activator deficiency. *Oral Surg Oral Med Oral Pathol.* 1988;66:680-682.
126. Schofield JJ. Complications of dental extractions in patients receiving anticoagulant therapy [letter]. *Br Dent J.* 1984;156:200.
127. Sheller B, Tong D. Dental management of a child on anticoagulant therapy and the International Normalized Ratio: case report. *Pediatr Dent.* 1994;16:56-58.
128. Somma F, Grande NM, Plotino G, Camelli G, Pameijer CH. Conservative approach to dental extractions in patients on anticoagulant therapy: a clinical study. *Gen Dent.* 2010;58:e30-e35.
129. Todd DW. Outpatient use of low-molecular weight heparin in an anticoagulated patient requiring oral surgery: report of a case. *J Oral Maxillofac Surg.* 2001;59:1090-1092.
130. Wilson SJ, Morgan J, Gray L, Newman V, Anderson DR. A model of peri-operative outpatient management of anticoagulation in high-risk patients: an evaluation of effectiveness and safety. *Can J Hosp Pharm.* 2001;54:269-277.
131. Wood JC, Conn HL. Prevention of systemic arterial embolism in chronic rheumatic heart disease by means of protracted anticoagulant therapy. *Circulation.* 1954;10:517-523.
132. Yasaka M, Naritomi H, Minematsu K. Ischemic stroke associated with brief cessation of warfarin [letter]. *Thromb Res.* 2006;118:290-293.
133. Douketis JD, Spyropoulos AC, Spencer FA, et al. Peri-operative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2012;141:e326S-e350S.
134. Todd DW. Anticoagulated patients and oral surgery [Letter]. *Arch Intern Med.* 2003;163:1242.
135. Balevi B. Should warfarin be discontinued before a dental extraction? A decision-tree analysis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2010;110:691-697.
136. Wahl MJ. Bleed or die? A bloody simple decision [letter]. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2012;113:147-148.
137. Todd DW. Evidence to support an individual approach to modification of anticoagulant therapy for ambulatory oral surgery. *J Oral Maxillofac Surg.* 2005;63:536-539.
138. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of

- Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141:e576S-e600S.
139. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. *Chest*. 2001;119:22S-38S.
140. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh AACP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:204S-233S.
141. Douketis JD, Berger PB, Dunn AS, et al. The peri-operative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. *Chest*. 2008;133:299S-339S.
142. Beirne OR. Anticoagulation and minor oral surgery: should the anticoagulation regimen be altered? [discussion]. *J Oral Maxillofac Surg*. 2000;58:135-136.

Reprint requests:

Michael J. Wahl, DDS
2003 Concord Pike
Wilmington
DE 19803
302-655-1228
WahlDentistry@aol.com